In-Person Access Only | TBD CE/CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
The Pathways: Intersection of Solid and Hematologic Malignancies 2026 meeting will take place on September 25-26, 2026. This innovative and state of the art program will be led by Naveen Pemmaraju, MD, Professor, Department of Leukemia, MD Anderson Cancer Center and Naval Daver, Director, Leukemia Research Alliance Program, Professor of Medicine, Department of Leukemia, MD Anderson Cancer Center.
Conference Agenda
Saturday, September 25, 2026
7:30 AM
Coffee and Exhibits
7:55 AM
Founding Program Chairs Welcome
Naveen Pemmaraju, MD | UT MD Anderson
Naval Daver, MD | UT MD Anderson
8:00 AM
Targeted Therapies in Myelodysplastic Syndrome in 2025 and Beyond: Present & Future Directions
Guillermo Garcia-Manero, MD | UT MD Anderson
8:20 AM
Targeting RAS in Solid Tumors in the Phase I Clinic: Emerging Clinical Trials
David Hong, MD | UT MD Anderson
8:40 AM
Panel Discussion: Novel Pathways in MDS and Pancreatic Cancer/Solid Tumors
Naveen Pemmaraju, MD | UT MD Anderson
Naval Daver, MD | UT MD Anderson
Guillermo Garcia-Manero, MD | UT MD Anderson
David Hong, MD | UT MD Anderson
9:10 AM
Breakfast and Exhibits
9:25 AM
Non-CME Breakfast
Session #1: TP53
Moderator: Michael Andreeff, MD, PhD | UT MD Anderson
10:10 AM
Modulating TP53 in Human Cancer : Future Directions and Implications for Clinical/Translational Development
Guillermo Garcia-Manero, MD | UT MD Anderson
10:25 AM
TP53 DX and Classification in MDS and AML: Hematopathologists' Perspective
Sanam Loghavi, MD | UT MD Anderson
10:40 AM
Targeting TP53 in H&N Cancer
Jeffrey Myers, MD, PhD, FACS | UT MD Anderson
10:55 AM
Targeting TP53 for AML: from Bench to Bedside: Future Directions
Michael Andreeff, MD, PhD | UT MD Anderson
11:10 AM
Venetoclax Treatment in MDS: Biological Insights
Simona Colla, PhD | UT MD Anderson
11:25 AM
Panel Discussion on Targeting RAS/RAF Across Solid and Liquid Tumors
Michael Andreeff, MD, PhD | UT Md Anderson
Jeffrey Myers, MD, PhD, FACS | UT MD Anderson
Simon Colla, PhD | UT MD Anderson
11:55 AM
Emerging Novel Agents in Development for Sarcoma
Neeta Somiah, MD | UT MD Anderson
12:10 PM
Lunch and Exhibits
12:25 PM
Non-CME Lunch
Session #2: Targeting RSA/RAF: The Previously Undruggable Target now Targetable
Moderators: Scott Kopetz, MD, PhD | UT MD Anderson & David Hong, MD | UT MD Anderson
1:10 PM
Targeting RAS/RAF Across Human Malignancies: Progress at the Bench
Tim Heffernan, PhD | UT MD Anderson
1:25 PM
Targeting BRAF in Colon Cancer
Scott Kopetz, MD, PhD | UT MD Anderson
1:40 PM
Panel Discussion: Targeted Therapies in Leukemia & MDS
Scott Kopetz, MD, PhD | UT MD Anderson
Tim Heffernan, PhD | UT MD Anderson
David Hong, MD | UT MD Anderson
2:00 PM
Break and Exhibits
Session #3: Targeting IDH in Heme/Solid Tumors
2:10 PM
Targeting IDH1 & 2 Mutations in AML
Courtney DiNardo, MD, MSCE | UT MD Anderson
2:25 PM
Targeting IDH Mutations in Cholangiocarcinoma
Milind Javle, MD | UT MD Anderson
2:40 PM
Panel Discussion
Courtney DiNardo, MD, MSCE | UT MD Anderson
Milind Javle, MD | UT MD Anderson
3:00 PM
Future Directions for CAR-T in Hematologic & Solid Cancers and Autoimmune Diseases
Elizabeth Shpall, MD | UT MD Anderson
3:15 PM
ADJOURN
Saturday, September 25, 2026
7:00 AM
Breakfast and Exhibits
7:15 AM
Non-CME Breakfast
8:00 AM
Founding Program Chairs Welcome
Naveen Pemmaraju, MD | UT MD Anderson
Naval Daver, MD | UT MD Anderson
8:05 AM
Remarkable Progress in Targeted Therapies in Acute Lymphoblastic Leukemia 2000-2025
Hagop Kantarjian, MD | UT MD Anderson
8:35 AM
Novel Targeted Therapies/New Pathways of Interest in DLBCL
9:05 AM
Break
Session #4: CAR-T
Moderator: Sattva Neelapu, MD | UT MD Anderson
9:15 AM
CAR-T in Lymphoma: Time to Move into Frontline?
Sattva Neelapu, MD | UT MD Anderson
9:30 AM
CAR-T in B-ALL
9:45 AM
CAR-T in T-ALL
Nitin Jain, MD | UT MD Anderson
10:00 AM
Panel Discussion
Nitin Jain, MD | UT MD Anderson
Sattva Neelapu, MD | UT MD Anderson
10:30 AM
Break and Exhibits
Session #5: Developing Targets in Rare Cancers, Part 1
Moderators: Naval Daver, MD & Courtney DiNardo, MD, MSCE | UT MD Anderson
10:45 AM
Development of YAP/TEAD Inhibitors: Targeting Hippo Pathway
Tim Yapp, MBBS, PhD, FRCP | UT MD Anderson
11:00 AM
Targeting PPP2R1A Mutations in Ovarian Clear Cell Carcinoma
Amir Jazaeri, MD | UT MD Anderson
11:15 AM
Panel
Amir Jazaeri, MD | UT MD Anderson
Naval Daver, MD | UT MD Anderson
Tim Yap, MBBS, PhD, FRCP | UT MD Anderson
Courtney DiNardo, MD, MSCE | UT MD Anderson
11:45 AM
Lunch and Exhibits
12:00 PM
Non-CME Lunch
Session #6: Emerging Targets in Oncology
Moderator: Naveen Pemmarjau, MD | UT MD Anderson
12:45 PM
Novel Approaches for Treatment of Breast Cancer in Setting of BRCA1 and BRCA2 Mutations
Jennifer Litton, MD | UT MD Anderson
1:00 PM
Panel Discussion
Naveen Pemmaraju, MD | UT MD Anderson
Jennifer Litton, MD | UT MD Anderson
1:30 PM
Break and Exhibits
Session #7: Antibody and Cell Based Therapies in Heme Malignancies
1:45 PM
Targeting CD123 in Heme Malignancies
Naveen Pemmaraju, MD | UT MD Anderson
2:00 PM
CLOSING REMARKS & ADJOURN
Naveen Pemmaraju, MD | UT MD Anderson
Naval Daver, MD | UT MD Anderson
Agenda Subject To Change. All times are CST.
-
-
-
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources